Friedreich Ataxia Clinical Trial
Official title:
Exploration of Transitional Life Events in Individuals With Friedreich's Ataxia: Implications for Genetic Counseling
The purposes of this study are to learn about significant life changes for people with
Friedreich's ataxia and about patients' experiences with health care providers. Friedreich's
ataxia is a rare genetic disorder in which patients experience progressive muscle weakness
and loss of coordination in the arms and legs. They may have other complications, such as
vision and hearing impairment, dysarthria, scoliosis, diabetes, and heart disease. The study
will explore the impact of this chronic progressive illness on transitional life events,
such as career choice and marriage, and the role of family members and health care
providers-particularly genetic counselors-in helping patients progress through these events.
Patients with Friedreich's ataxia who are 18 years of age or older may be eligible for this
study. Those enrolled will participate in a 45- to 60-minute interview by phone or in
person, in which they will be asked questions about important changes in their lives and
their past experiences with health care providers. The interview will be audiotaped.
Human development across the lifespan is a process of continual change, adaptation and
growth. Throughout this process, key transitional events, such as career choice and
marriage, mark important points in time when an individual's life course is significantly
altered. These transitional events may be instigated by age, historical or idiosyncratic
factors. Of particular interest in the present study are patients' perceptions of
transitional events brought about or altered by chronic illness and disability.
Additionally, factors (i.e. social support, communication, family) that help facilitate
progression through these events will be investigated. The actual or potential role of
health care providers during transitional events will also be explored with a specific
emphasis on genetic counseling. These themes will be examined through the administration of
a one-time, semi-structured, in-person or telephone interview of patients with Friedreich's
ataxia: a progressive, debilitating, neurodegenerative condition. The interviews will be
approximately 45-60 minutes in length and will include open-ended questions to elicit
qualitative data. Approximately 40 subjects will be recruited from Friedreich's ataxia
support groups, a research organization and a clinical setting.
It is anticipated that data elicited from the study will lead to recommendations regarding
the process and content of genetic counseling for individuals with Friedreich's ataxia.
These considerations, coupled with qualitative data obtained from participants, may also
have implications for the evolving role of the genetic counselor. Specifically,
consideration of developmental counseling approaches, which emphasize key transitional
events, may be particularly useful as genetic counselors become increasingly involved in
subspecialties (i.e. cardiology, pediatrics, neurology) that provide continuing follow-up
care to patients.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05573698 -
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
|
Phase 1 | |
Completed |
NCT00229632 -
Idebenone to Treat Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT05579691 -
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
|
Phase 2 | |
Completed |
NCT04273165 -
Safety and Efficacy of Etravirine in Friedreich Ataxia Patients
|
Phase 2 | |
Not yet recruiting |
NCT05874388 -
Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia
|
N/A | |
Completed |
NCT02594917 -
Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
|
||
Completed |
NCT01716221 -
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
|
Phase 4 | |
Active, not recruiting |
NCT05485987 -
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
|
Phase 2 | |
Completed |
NCT03214588 -
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
|
Phase 2 | |
Completed |
NCT03418740 -
Neurology Measures in FA Children
|
||
Not yet recruiting |
NCT06054893 -
A Study of Omaveloxolone in Children With Friedreich's Ataxia
|
Phase 1 | |
Recruiting |
NCT04921930 -
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
|
Phase 1/Phase 2 | |
Completed |
NCT03933163 -
Micronised Resveratrol as a Treatment for Friedreich Ataxia
|
Phase 2 | |
Completed |
NCT02705547 -
Rosuvastatin (Crestor) in Friedreich Ataxia
|
Early Phase 1 | |
Completed |
NCT02035020 -
A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients
|
Phase 2 | |
Completed |
NCT00015808 -
Safety Study of Idebenone to Treat Friedreich's Ataxia
|
Phase 1 | |
Completed |
NCT04817111 -
NAD+ Precursor Supplementation in Friedreich's Ataxia
|
Phase 2 | |
Active, not recruiting |
NCT05168774 -
FRDA Investigator Initiated Study (IIS) With Elamipretide
|
Phase 1/Phase 2 | |
Completed |
NCT03917225 -
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
|
Phase 2 | |
Completed |
NCT00224640 -
Iron-Chelating Therapy and Friedreich Ataxia
|
Phase 1/Phase 2 |